WINN FIP SYMPOSIUM

PURRsuing FIP and WINNing

NOVEMBER 16 & 17, 2019
UNIVERSITY OF CALIFORNIA AT DAVIS, CALIFORNIA

Winn Feline Foundation has a long and outstanding tradition of bringing

together the top experts in feline medical research for educational events
that cover the most important and relevant information on the topic.
This condensed summary from Winn’s November 2019 symposium,
PURRsuing FIP and WINNing, will help cat advocates everywhere
understand that feline infectious peritonitis (FIP) is now a treatable disease.

Copyright © Winn Feline Foundation, 2020

FELINE CORONAVIRUS
Feline coronaviruses (FCoV) occur in two biotypes: feline enteric coronavirus (FECV), and feline infectious peritonitis virus (FIPV),
which causes feline infectious peritonitis (FIP). FIP appears to be a relatively recent disease of cats—it was initially described in the
late 1950s by Dr. Jean Holzworth at Angell Memorial Animal Center in Boston. Have coronaviruses only recently emerged in cats
from another species? Did an earlier feline coronavirus mutate to more easily cause FIP? Is FIP a consequence of the post-World
War II increase in keeping cats as household pets and the emergence of shelters, rescue groups, and catteries?

FELINE ENTERIC CORONAVIRUS (FECV)

Epizootiology and Pathogenesis1

• FECV is an enveloped, single-stranded RNA virus that is associated with

asymptomatic persistent enteric infections.
• It is found worldwide and is ubiquitous in domestic and wild Felidae.
• There are two serotypes: 80% to 95% are Serotype I (cat-like); 5% to 20%
are Serotype II (dog-like).
• Serotype II has a higher incidence in Asia than in North America and Europe.
• Clinically inapparent infection of kittens can start after weaning FIP is not a rare form of FECV
(nine to ten weeks of age). infection. It’s not just that most
cats get nothing and a few cats,
• Virus shedding in feces can persist for many weeks, months, or longer.
because of some peculiarity,
• Fecal-oral transmission is facilitated by shared litter boxes. get FIP. That’s what was thought
• The virus displays tropism for the mature apical epithelium of the lower intestine. for a long time. But when we
• Immunity develops slowly. finally were able to separate
the two diseases, we realized
• Immunity is lost after shedding ceases, and recurrent infections are common.
they’re different viruses. FIP
viruses cause FIP, FECV causes
Passive Systemic and Local Immunity2 enteric infections.

• Kittens can make IgM antibody and mount cell-mediated immune responses —Dr. Niels Pedersen
from birth.
• IgG and IgA antibodies are absorbed from colostrum during first few
hours of life.
• Passive systemic immunity results from IgG and IgA from colostrum.
• Passive local immunity is derived from IgG and IgA antibodies in the milk.
• Passive systemic and local immunity protect kittens until their immune
system matures.
• IgG and IgA production does not start until passive antibody protection is gone
(six to eight weeks of age).
• Kittens’ immune systems do not reach adult levels until 12 to 16 weeks of age.

Copyright © Winn Feline Foundation, 2020 2

Immunity to FECV Infection2
• Kittens born to FECV-exposed queens will have maternal immunity until nine
weeks of age.
• Primary infection will evoke both a systemic and a local antibody response.
• IgA goes from blood transmitted across the intestinal epithelium into the mucous. A pretty remarkable protection
• There is no evidence of cell-mediated immunity or any changes in results from passive maternal
lymphocyte populations. antibody. That shows something
about what can protect cats
• The IgA antibody response slowly leads to cessation of virus shedding.
against FECV.
• Antibody titers wane as virus shedding ceases, and cats become susceptible
to reinfection. —Dr. Gregg Dean

• Immunity to FECV infection is transient and recurrent infections are common.

FELINE INFECTIOUS PERITONITIS

VIRUS (FIPV)
Origins of FIPV1
• FIPV arises from FECV infection by mutation.
• FIPVs occur in regional lymphoid tissues of the lower intestine in 10%
of FECV-infected cats.
• Mutations result from positive selection pressures favoring replication
in macrophages.
• FIPVs acquire tropism for peritoneal macrophages and lose tropism for
intestinal epithelium.
• Tropism change results from mutations in Spike (S, S1/S2) and accessory 3c genes.
• FIPV mutation is unique to each cat.
• FIPVs are strictly cell-associated, and local and systemic spread is in monocytes/
macrophages.
• FIPV is confined to infected macrophages, which are not spread from cat to cat.
• There are rare cases of cat-to-cat spread (epidemic form) by Serotype II FIPVs.

FELINE INFECTIOUS PERITONITIS (FIP)

FIP Epizootiology1,3
• FECV infection occurs in virtually all cats and kittens.
• FECV-to-FIPV biotype conversion occurs in 11% of cats.
• Only 1:10 to 1:30 cats with mutant viruses develop FIP.
• Worldwide, feline mortality among all cats due to FIP is thought to be 0.3% to 1.3%.
• FIP favors multi-cat environments—catteries, foster homes, rescue groups, shelters, and cats living in dense urban areas.
If there is additional stress in these environments, the odds of FIP occurring increases.
• 95% of cases occur in cats less than seven years of age, 70% in cats less than 1.5 years of age, 50% in cats less than seven
months of age.
• Pedigreed cats have three times greater incidence of FIP than random-bred cats.
• Males are slightly more susceptible.

Copyright © Winn Feline Foundation, 2020 3

FIP Pathogenesis
• Macrophages are infected by immune complex virus through their Fc receptors.
• FIP is typical of other macrophage infections, such as tuberculosis, leprosy, and deep mycoses.
• FIP is mediated by cytokine responses of infected macrophages.
• Th1 (cell-mediated) cytokine responses are protective.
• Protective immunity is innate at onset and then becomes adaptive (active).
• Failure to establish protective immunity leads to a Th2 (inflammatory) response and disease.
• Affected cats have delayed apoptosis of infected macrophages, allowing for increased virus production.
• The incubation period from first replication in macrophages to clinical disease is days to months.
• The actual disease course varies from days to months and, rarely, a year or more.
• Once typical disease signs appear, historically, fewer than 5% of affected cats have survived to one year.

Two Disease Forms of FIP

• There are two major disease forms: effusive (wet, non-granulomatous, non-parenchymatous) and non-effusive
(dry, granulomatous, parenchymatous).
• Wet and dry FIP resemble the lepromatous and tuberculoid forms of human leprosy, respectively.
• The two forms of FIP are dependent on the relative balance of cellular (Th1) and humoral (Th2) immune responses.
• Wet FIP is characterized by a predominance of immediate hypersensitivity reactions (vasculitis) and high levels
of virus replication in macrophages.
• Dry FIP is characterized by a predominance of delayed hypersensitivity reactions and low levels of virus replication
in macrophages.
• The disease form in a cat may change from wet FIP to dry FIP, or dry to wet, during the course of the illness.

What determines form of FIP?

Wet FIP Dry FIP Immunity

Antibodies; Antibodies; Antibodies;

No cell-mediated Weak cell-mediated Strong cell-mediated
immunity immunity immunity

Copyright © Winn Feline Foundation, 2020 4

DIAGNOSING FIP4,5
In most cases a diagnosis of FIP can confidently be made by obtaining a complete
history and performing a thorough exam of the patient, then using the following
For any infectious disease, there
diagnostic tools to build a “diagnostic wall,” brick by brick. Various test results
consistent with FIP can provide strong evidence for the diagnosis. needs to be four legs to the stool:
• A good diagnostic test
Signs and Symptoms • A good therapeutic treatment
• High index of suspicion and playing the odds* • A good vaccine
• Signalment: age, breed, origin (shelter/sanctuary or other dense multi-cat • A good environmental
situations) control plan

• Sudden loss of activity, lethargy, anorexia, weight loss —Dr. Elizabeth Colleran
• Failure to thrive (smaller than normal, poor hair coat, thin)
• Cyclical (waxing/waning), antibiotic-unresponsive fever
• Recent stressful event (vaccinations, surgery, new home, relinquished to a shelter or foster home, other illnesses, etc.)
• Physical exam and presence of signs associated with FIP: jaundice, ascites (abdominal distension) or pleural fluid (dyspnea),
uveitis or retinitis (may be unilateral), neurologic signs (ataxia, seizures, weakness), palpable abdominal masses
* The odds of making a diagnosis of FIP with minimal diagnostic testing depends on the clinician’s level of experience with the disease. Although FIP is one
of the most important infectious diseases of cats, the average veterinary practitioner may not see many cases unless they are working closely with shelters,
rescue groups, and/or breeders, or their practice is feline exclusive. The more difficult cases are often seen by specialists or university hospitals.

Basic Non-Definitive Tests

• CBC (anemia of chronic disease, leukocytosis, lymphopenia)
• Examination of ascites or pleural fluid (any effusion)
• Serum proteins (total protein-high, albumin, globulin-high, an A:G ratio of < 0.6 with the lowest A:G ratios tending
to be in cats with wet FIP rather than dry)
• Bilirubin is elevated in 21% to 63% of FIP cases, often without marked elevation in hepatic enzyme activity
• Feline coronavirus antibody titer (cannot determine if antibodies are against FECV or FIPV, and only if titers are 1:3200 or greater)
• Tests for serum proteins associated with inflammation and immune response:
• Serum protein fractionation
• AGP (alpha-1-glycoprotein) markedly elevated (> 3g/l)
• Detect and analyze abdominal and/or thoracic effusions:
• Yellow-tinged (due to bilirubin from RBC breakdown)
• Mucinous (sticky or stringy)
Diagnosis of FIP, not always
• Partial clots when not anti-coagulated
an easy subject. I look back
• Cloudy (high RBC and WBC, fibrin tags) through my notes that I’ve
• Non-degenerative neutrophils, monocyte/macrophages, large foamy had as an undergraduate and
macrophages, lymphocytes there wasn’t a huge amount of
• Protein 2-10+ g/dl information on FIP because it
was a disease that was difficult
• Rivalta test (should not replace a complete fluid analysis, but the test
is inexpensive and easy to perform)6 to prove a diagnosis for. But
we do need to have an index of
• Imaging for evidence of effusion, and/or organ or central lymph node involvement:
suspicion that FIP is out there,
• Radiographs, ultrasound of abdomen and/or chest that it is a possibility.
• MRI scans with contrast (neurological FIP) —Dr. Emi Barker
• Ophthalmoscopy

Copyright © Winn Feline Foundation, 2020 5

If you confirm the presence
of FIP virus antigen or RNA
within peritoneal-type
Definitive Tests**
macrophages within typical This means FECV/FIPV RNA is identified in effusion or diseased tissues.
effusions or lesions, you have • Histopathologic or microscopic appearance of lesions is not pathognomonic
made a definitive diagnosis. unless combined with the rest of the clinical picture.
However, this is compounded • Immunohistochemistry is positive for coronavirus antigen in macrophages within
by all of the false negative effusions of diseased tissues.
test results that are made by
• Polymerase Chain Reaction (real time PCR) must have enough FIPV RNA in the
IHC or PCR by laboratories
effusion sample:
using poor techniques or
that have been given non- • FCoV 7b RNA PCR is most sensitive; FIPV S mutation RNA test is less sensitive
representative samples (i.e., • Positive 7b RNA test is diagnostic even if the S mutation test is negative
samples containing either • PCR on blood is not highly sensitive7,8,9
no or insufficient infected
macrophages). ** No test is definitive unless properly performed and truly positive. PCR and immunohistochemistry
—Dr. Niels Pedersen are falsely negative in about 30% of samples. False positives are uncommon. (Dr. Niels Pedersen)

TREATING FIP
• There are only two ways cats diagnosed with FIP can be cured:
• Find a way to stimulate a protective immune response.
• Completely inhibit FIPV replication long enough to clear the virus from
macrophages and/or to allow host immunity to develop.
• Symptomatic care (only to sustain life):
• Nutrition: high-protein (animal meat), low-carbohydrate diet
• Appetite stimulants
• Fluid therapy support
• Drain effusions only if necessary to prevent dyspnea or discomfort
• Prednisolone (low dose) to decrease inflammation and improve appetite
• Antibiotics are frequently given but have no significant effect on virus
infections (doxycycline has been reported to have antiviral activity for
several viruses)
• Immunostimulants:
• Feline interferon omega—no evidence of efficacy
• Polyprenyl immunostimulant—there is some evidence of efficacy in 8%
of dry FIP cases when used as a sole treatment10,11
• Non-specific antiviral compounds: Several drugs and biologics inhibit viral
An accurate diagnosis and replication by inhibiting normal cellular processes that are usurped by viruses
starting treatment as soon to aid in their replication. However, effective viral inhibition cannot be achieved
as possible are paramount to without significant cellular toxicity.
giving any cat with FIP the best • Itraconazole, cyclosporine, chloroquine, several antibiotics, and many
chance to live and be cured. plant extracts
—Susan Gingrich, • Antiviral drugs specifically targeting viral proteins (the treatment of choice):12
Bria Fund founder • RNA transcription inhibitors (nucleoside analogs)—GS-44152413
• 3CL viral protease inhibitors—GC-37614,15

Copyright © Winn Feline Foundation, 2020 6

Current Non-FDA-Approved Antiviral Drug Status
• FIP is now considered a curable disease.
• Anecdotally, thousands of cats worldwide have been treated and possibly cured with antiviral compounds.
Reversal of severe signs for both wet and dry forms of FIP (fever, loss of appetite, weakness, effusions/bloated
abdomen, uveitis, neurological) can be seen within just days to weeks after starting antiviral treatment.
• The currently known drug with the most significant success for curing FIP is GS-441524, a nucleoside analog
produced by Gilead Sciences, which is under patent and not available for veterinary use.
• Anivive Lifesciences, Inc. is working to gain FDA approval of GC-376 as a treatment for FIP.

Unresolved Concerns Regarding Non-FDA-Approved Antiviral Compounds

• Several companies in China have developed what they suggest are similar or the same compound/drug/products
(these are unidentified products but they are reported to be nucleoside analogs) and are marketing these products
worldwide as “dietary supplements” to treat FIP.
• The compounds have not received GRAS (generally recommended as safe) status. Under US FDA restrictions,
the use of non-GRAS compounds in veterinary healthcare is illegal.
• Those treating cats with FIP are acquiring a version of GS-441524 through online or non-veterinary resources
(such as members of the public referred through Facebook groups).
• Be sure to closely read the Terms of Service on a company’s website.
• No assurances are available as to bioactivity, safety, toxicity, and identity of the compounds being used in
these non-FDA-approved substances.
• The course of treatment recommended can be expensive. Prices vary among companies and whether cost
is related to the quality of the product remains unknown. Suppliers of GS-441524 should be chosen with care.
• No centralized data is being maintained or reviewed under scientific supervision.
• Veterinarians cannot prescribe or dispense these non-approved compounds.
They can, though, choose to provide supportive and monitoring care for cats
undergoing treatment.
• Establishing a good veterinarian-client-patient relationship is in the best
interests of the patient.

PREVENTING FIP
Vaccination
• The reputation for failure of previous vaccines has slowed the process of
vaccine development.
• Growing virus in cell culture is critical to vaccine development. Of the two
serotypes, Type I is most common in North America but Type II is easier to While a single-dose vaccine that
grow and more common in Asia.16 induces strong lifelong immunity
• Vaccine development has also been hampered by the inability to grow FECV is the most desirable, it may be
Serotype I, so the current vaccine is directed against the less common and more efficient to tailor a vaccine
less pathogenic Serotype II. to an intended use, such as a
• Vaccine-induced antibody-dependent enhancement, in which the presence strong, rapidly effective vaccine
of specific antibodies can be beneficial to the virus, is a concern. This occurs with short duration of immunity
when the vaccine induces a sub-neutralizing antibody response instead for shelter environments, where
of a sterilizing response. One possible route to an effective vaccine is to exposure is brief.
reengineer the attenuated virus to induce stronger immunity. —Dr. Gregg Dean

Copyright © Winn Feline Foundation, 2020 7

 • New high-throughput technologies are improving the chances of developing a vaccine by working
backward from an understanding of the immune response to FIP and using that for a rational design.
• Mutant virus and cell line research must investigate and illuminate the role of interferon to successfully
develop vaccines. This work is underway.
• In an effort to preserve the genetic diversity of various cat breeds, there may be more cats imported into
North America from Asia, where Serotype II is more common.
• Respiratory transmission of FECV has been achieved in Serotype II, which may complicate vaccine development.
• Given enough time and money, if an effective vaccine is developed, perhaps such a vaccine should be administered
only to kittens or cats most at risk, such as in shelters, rescue groups, sanctuaries, and pedigreed cat breeders.

Virus Volume and Stress

It’s like a roll of the dice if • Stressful conditions have a tremendous impact on virus shedding.
you’re going to get FIP out of • There are multiple mutations that cause disease from reservoirs of FECV
a coronavirus. And it’s really in crowded conditions.
different to roll the dice once
• Every virus shed is an experiment in potential mutation and exposure
than to roll it 10,000 or a million of cats to that mutation.
times. We are increasing the risk
• Reducing the environmental viral load is a critical component in prevention.
that it’s going to turn into FIP.
• Stress appears to trigger disease in some cats. However, tools for accurately
—Dr. Kate Hurley
analyzing stress triggers may be somewhat lacking.
• Nutrition, lack of passive immunity for orphan kittens, and gastrointestinal
dysbiosis are all worthy of investigating as possible stressors.
• Distinguishing the role of stress from the role of comorbid conditions is not
yet possible.

Immunity
• Strong immune response and virus elimination may occur for only a period
of time.
• FECV does NOT induce durable immunity. Immunity wanes and cats
become susceptible again.
• Passive maternal antibodies are highly protective and may be useful in
creating more durable immunity.

There’s an immune response • Innate cellular immunity is required, which in turn requires growing FECV
Serotype I in cell culture for vaccine development.
that seems to possibly eliminate
the virus maybe for some period
of time, but the immunity wanes Genetic Resistance or Susceptibility
and cats are susceptible again.
• 11% of cats develop the FIP biotype mutations, but only a fraction of
—Dr. Gregg Dean those become sick. Identifying the genetic component for this is crucial.
• While pedigreed cats have increased susceptibility, it appears that all cats
of a particular breed do not seem to be susceptible. Rather, particular
Is there a genetic reason why lineages within a breed have high susceptibility.
11% of cats infected with FIP • The reverse must then be true—there are lineages that have genetic resistance.
virus don’t eventually go on to • There may be an interferon gamma gene that could be a marker for
develop FIP? increased risk.
—Dr. Leslie Lyons • Other markers may also exist, given the complexity of this disease.

Copyright © Winn Feline Foundation, 2020 8

Environmental Control
• According to a recent study,17 certain bentonite-based cat litters can decrease viral shedding and environmental
contamination. However, the clinical significance has not yet been demonstrated.
• Early weaning of kittens is not desirable, as passive immunity from colostrum (IgG) and lactation (IgA) can effectively
protect kittens from coronavirus infection.
• A coronavirus-free environment is not practical, as reinfection is nearly impossible to prevent.

MULTI-CAT ENVIRONMENTS
Shelters What is the best way to care for
kittens in catteries, shelters, and
• In well-run shelters today, FIP is not a common problem.
rescues to minimize FIP losses?
• A well-functioning shelter should see less than 1% FIP cases (fewer than
—Dr. Niels Pedersen12
ten cases per 1,000 cats).
• Shelters should balance intake with healthy outcomes by reduced crowding,
thus decreasing virus shedding and exposure to infectious disease.
• One study showed that FECV shedding increased millions-fold in some cats
after a week in the shelter.3
• Developing fostering programs, so bottle-raised kittens or queens with
kittens do not come into the shelter but go straight into foster homes,
lessens the odds of exposure to all infectious diseases, including FIP.
• Using double compartment enclosures with 8.5 square feet of floor space
leads to a 50% decrease in exposure to upper respiratory infections (URIs).
• Placing portals between compartments decreases the incidence of respiratory
disease by 90%.
• Group housing is not ideal for cats. If grouped, place no more than three
to five cats in each group.18
• Keep the group stable—no in and out movement of cats. Don’t mix
short-stay and long-stay cats.
• If you want to be a cat sanctuary, be a sanctuary. Don’t mix being a shelter
and a sanctuary.
• “Don’t kit-nap kittens” program: If a litter of kittens is found, encourage the
public to leave them alone and see whether the queen returns—which can I’m not here to teach you about
take up to 15 hours or more.19 how to treat infectious diseases.
• If kittens are not socialized, consider trap-neuter-return (TNR) to place them I’m here to explain to you how
back in their cat colony. to do surveillance, and how to
prevent them.
• Early age spay and neuter of kittens at 1.5 pounds to increase their
adoptability poses no increased health risk to them. —Dr. Gary Whittaker

We must find ways to keep cats out of shelters to prevent exposure and work with community partners to not bring in
kittens to shelters. We need to raise up cats or increase the means to help adopt more cats out that are healthier, or in
other situations to trap, neuter, and return cats back to their normal environments.
—Dr. Kate Hurley

Copyright © Winn Feline Foundation, 2020 9

Rescue Groups
• Shelters and other animal welfare groups need to offer tools and mentoring
to rescue groups for infectious disease control.
• Rescues are trying to do too much and thus increase direct exposure to
infectious diseases.
• A consistent TNR (trap-neuter-return) program usually leads to healthier cat
colonies.

Catteries
• Elimination of FIP from a cattery is only possible by total elimination of FECV.
• It is not possible to test and eliminate FECV from a cattery because FECV is
ubiquitous in cat environments.
• Pedigreed cats producing kittens with FIP should not be used for breeding,
including those pedigreed cats who have been cured of FIP.

CONCLUSION
Our mission to end FIP is not finished. Research must continue in such areas as
improving diagnostic methods, developing additional antiviral drugs, and especially This is a treatable disease.
strategies to prevent FIP infection in cats. We will cure this disease. We
basically have the cure now;
Winn Feline Foundation is at the forefront of funding FIP-related research. it’s just a matter of finding the
Winn’s Bria Fund for FIP Research is instrumental in providing grants MT13-006, exact right drug and the right
W13-020, W15-010, W16-022, MTW17-020, W19-026 toward the development of combination (of drugs) and then
the new antiviral drugs, GC-376 and GS-441524. Additional grants in recent years, making those available at an
such as MT16-014, W16-023, W16-024, W17-021, MTW17-022, W18-007, W18-010, affordable price.
W19-024, W19-025, and W19-027, are funding research into new FIP diagnostics,
other FIP antiviral drugs, and vaccine development. Winn thanks our generous —Dr. Brian Murphy
donors to the Bria Fund for supporting this critically needed research.

For a list of FIP projects funded by Winn’s Bria Fund for FIP Research, see:
https://www.briafundsupporters.com/studies
https://www.winnfelinefoundation.org/grants/grant-awards

How to use social media to find the best information to help cat parents:
Winn Feline Foundation: www.winnfelinefoundation.org
Bria Fund for FIP Research Supporters: www.briafundsupporters.com
SOCK FIP: sockfip.org
Zen By Cat: www.zenbycat.org
Words used by attendees to
Veterinary Information Network (VIN): www.vin.com describe this symposium:
FIP Warriors Facebook Group for Cat Parents: wow, hope, curable, winning,
www.facebook.com/groups/158363205096283/ exciting, inspirational,
FIP Warriors Facebook Group for Veterinarians: networking, future, passion,
www.facebook.com/groups/2422765211310743/ fantastic, best, authoritative
[email protected]

Copyright © Winn Feline Foundation, 2020 10

AUTHORS

Niels C. Pedersen, DVM, PhD (Special Recognition)

Elizabeth Colleran, DVM, DABVP (feline)
Steve Dale, CABC
Susan Gingrich
Leslie Lyons, PhD
Vicki Thayer, DVM, DABVP (feline)
Drew Weigner, DVM
Editor: Beth Adelman, MS

SYMPOSIUM PANELISTS AND PRESENTERS

Emi Barker, BSc, BVSc, PhD, DipECVIM-CA, Honorary Research Associate, Langford House
David Bruyette, DVM, DACVIM (SAIM), CMO, Anivive Lifesciences
Elizabeth Colleran, DVM, DABVP (feline), Chico Hospital for Cats
Peter Cohen, President, ZenByCat
Steve Dale, CABC, Board of Directors of Winn Feline Foundation
Gregg Dean, DVM, PhD, Professor and Department Head, Microbiology, Immunology, and Pathology, College of Veterinary
Medicine, Colorado State University
Susan Gingrich, Bria Fund Chairperson, Winn Feline Foundation
Katrin Hartmann, Dr. med. vet., Dr. habil., DECVIM-CA, Professor, Chief of Staff, SAM Clinic, Ludwig Maximilian University
Kate Hurley, DVM, MPVM, PhD, Director, Koret Shelter Medicine Program, University of California–Davis
Anthony Hutcherson, Board of Directors of Winn Feline Foundation, Jungletrax Bengals
Katie Ingram, Animal Services Manager, Placer County Animal Services
Heather Kennedy, DVM, Director of Feline Operations, KC Pet Project
Yunjeong Kim, DVM, PhD, DACVM, Associate Professor, CVM, Kansas State University
Barbie Laderman-Jones, DVM, DABVP, Director of Shelter Medicine, San Francisco SPCA
Al Legendre, DVM, PhD, DACVIM, Professor Emeritus, CVM, University of Tennessee
Leslie Lyons, PhD, Professor of Comparative Medicine, CVM, University of Missouri
Brian Murphy, DVM, PhD, DACVP, Associate Professor, CVM, University of California–Davis
Glenn Olah, DVM, PhD, DABVP (feline), Board of Directors of Winn Feline Foundation
Niels Pedersen, DVM, PhD, Professor Emeritus, CVM, University of California–Davis
Debra Roberts, RN, BSN C-EFM, has an FIP survivor cat from clinical trial
Vicki Thayer, DVM, DABVP (feline), Board of Directors of Winn Feline Foundation
Drew Weigner, DVM, President Board of Directors of Winn Feline Foundation
Gary Whittaker, PhD, Professor of Virology, Cornell University CVM

SYMPOSIUM SPONSORS

Anivive Lifesciences
Cat Fanciers’ Association
Dr. Elsey’s
KindredBio
Royal Canin, Mars, Inc
The International Cat Association
Zoetis
Host: University of California, Davis, School of Veterinary Medicine

Copyright © Winn Feline Foundation, 2020 11

REFERENCES

1. P
 edersen NC. An update on feline infectious peritonitis: 11. Legendre AM, et al. Polyprenyl immunostimulant treatment
Virology and immunopathogenesis. Vet J. 2014 of cats with presumptive non-effusive feline infectious
Aug; 201(2):123-132. https://www.ncbi.nlm.nih.gov/ peritonitis in a filed study. Front Vet Sci. 2017 Feb 14;4:7.
pubmed/24837550 https://www.ncbi.nlm.nih.gov/pubmed/28261584

2. P
 earson M, LaVoy A, Dean GA, et al. Mucosal immune 12. P
 edersen NC. Fifty years’ fascination with FIP culminates
response to feline coronavirus infection. Viruses. in a promising new antiviral. J Feline Med Surg. 2019
2019 Sept 27; 11(10). https://www.ncbi.nlm.nih.gov/ Apr; 21(4):269-270. https://www.ncbi.nlm.nih.gov/
pubmed/?term=Pearson+M%2C+Dean+GA+and+2019 pubmed/30905279

3. P
 edersen NC, Sato R, Foley JE, Poland AM. Common virus 13. Pedersen NC, Perron M, et al. Efficacy and safety of the
infections in cats, before and after being placed in shelters, nucleoside analog GS-441524 for treatment of cats with
with emphasis on feline enteric coronavirus. J Feline Med naturally occurring feline infectious peritonitis. J Feline
Surg. 2004 Apr; 6(2), 83-88. https://www.ncbi.nlm.nih.gov/ Med Surg. 2019 Apr; 21 (4):271-281. https://www.ncbi.nlm.
pubmed/15123152 nih.gov/pubmed/30755068

4. Pedersen NC. An update on feline infectious peritonitis: 14. Kim Y, Lui H, Pedersen NC, et al. Reversal of the
Diagnostics and therapeutics. Vet J. 2014 Aug; 201(2):133- progression of fatal coronavirus infection in cats by a
141. https://www.ncbi.nlm.nih.gov/pubmed/24857253 broad-spectrum coronavirus protease inhibitor. PLOS
Pathog. 2016 May 11; 12(5). https://www.ncbi.nlm.nih.gov/
5. F
 elten S. Hartmann K. Diagnosis of feline infectious pubmed/27166862
peritonitis: A review of the current literature. Viruses.
2019 Nov 15; 11(11). https://www.ncbi.nlm.nih.gov/ 15. Pedersen NC, Kim Y, et al. Efficacy of a 3C-like
pubmed/31731711 protease inhibitor in treating various forms of acquired
feline infectious peritonitis. J Feline Med Surg. 2018
6. Fischer Y, Hartmann K, et al. Diagnostic accuracy of the Apr; 20(4):376-392. https://www.ncbi.nlm.nih.gov/
Rivalta test for feline infectious peritonitis. Vet Clin Pathol. pubmed/28901812
2012 Dec; 41(4):558-567. https://www.ncbi.nlm.nih.gov/
pubmed/22913882 16. W
 hittaker GR, et al. Generating and evaluating type
1 interferon receptor-deficient and feline TMPRSS2-
7. Emmler L, Felten S, Hartmann K, et al. Feline coronavirus expressing cells for propagating serotype 1 feline
with and without spike gene mutations detected by infectious peritonitis virus. Virology. 2019 Nov; 537:226-
real-time PCRs in cats with feline infectious peritonitis. 236. https://www.ncbi.nlm.nih.gov/pubmed/31539770
J Feline Med Surg. 2019 Nov 15. https://www.ncbi.nlm.nih.
gov/pubmed/?term=Emmler+L%2C+Felten+S+and+2019 17. Addie D, Houe L, Maitland K, Passatino G, Decaro
N. Effect of cat litters on feline coronavirus
8. W
 hittaker GR, Jaimes JA. A tale of two viruses: The distinct infection of cell culture and cats. J Feline Med
spike glycoproteins of feline coronaviruses. Viruses. Surg. 2019 May 16. https://www.ncbi.nlm.nih.gov/
2018 Jan. https://www.ncbi.nlm.nih.gov/pubmed/31936749 pubmed/?term=Addie+D%2C+Houe+L+and+2019

9. Licitra BN, Whittaker GR, et al. Mutation in spike protein 18. D

 IY Housing Accessories for Animal Shelters. Koret
cleavage site and pathogenesis of feline coronavirus. Emerg Shelter Medicine Program. https://www.sheltermedicine.
Infect Dis. 2013 Jul; 19(7):1066-1073. https://www.ncbi.nlm. com/wp-content/uploads/2019/11/diy-housing-
nih.gov/pubmed/23763835 accessories-2ed_3.pdf

10. L egendre AM, Barges JW. Effect of polyprenyl 19. D

 on’t Kit-nap Kittens Program. https://www.azhumane.
immunostimulant on the survival times of three cats org/events/dont-kit-nap-kittens/?fbclid=IwAR0cxm_
with the dry form of feline infectious peritonitis. J Feline GmLgEjsITSs9DcULKMcnS6KnLq-cWfk9hkTtr6zvi1zQjeq81up8
Med Surg. 2009 Aug;11(8):624-626. https://www.ncbi.nlm.
nih.gov/pubmed/19482534

Copyright © Winn Feline Foundation, 2020 12